Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Bumbalo

Pulmonary Disease Myrtle Beach, SC Medical Doctor

NPI 1386759488 CMS profile 687915

906 Medical Cir, Myrtle Beach, SC 29572

Open in the dashboard

General payments

$5,362

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Bumbalo of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $5,362 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $218 8
2024 General $157 7
2023 General $772 22
2022 General $1,786 29
2021 General $279 7
2020 General $155 11
2019 General $1,994 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Bumbalo
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Thomas Bumbalo were reported at $218. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Thomas Bumbalo Pulmonary Disease median Middle half National median
2019 $1,994 $377 $109–$1,340 $163
2020 $155 $230 $56–$907 $114
2021 $279 $269 $68–$1,072 $132
2022 $1,786 $390 $100–$1,457 $149
2023 $772 $419 $114–$1,659 $160
2024 $157 $476 $123–$1,818 $164
2025 $218 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $2,010 23 payments
  2. GlaxoSmithKline, LLC. $705 31 payments
  3. Veran Medical Technologies, Inc. $427 6 payments
  4. Regeneron Healthcare Solutions, Inc. $297 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $283 18 payments
  6. Abbott Laboratories $252 12 payments
  7. Genzyme Corporation $240 8 payments
  8. Actelion Pharmaceuticals US, Inc. $145 20 payments
  9. Sunovion Pharmaceuticals Inc. $139 10 payments
  10. Astellas Pharma US Inc $134 4 payments
  11. Other $730 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,260 160 payments
  2. Travel and Lodging $1,553 6 payments
  3. Consulting Fee $300 1 payment
  4. Education $249 8 payments
Products named General payments · program years 2019–2025
  1. Monarch Platform $1,973 21 payments
  2. Spin $427 6 payments
  3. TRELEGY ELLIPTA $336 14 payments
  4. DUPIXENT Inflammation And Immunology $259 7 payments
  5. DUPIXENT Immunology $245 9 payments
  6. NUCALA $176 6 payments
  7. FreeStyle Libre 3 $166 8 payments
  8. UPTRAVI $145 20 payments
  9. OPSUMIT $145 20 payments
  10. SPIRIVA RESPIMAT $135 9 payments
  11. Other $1,390 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,855

Median for Pulmonary Disease: 936

Drug cost

$500,723

Median for Pulmonary Disease: $487,987

Branded share of claims

34.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 203 $217,065
Fasenra Pen Benralizumab Brand 19 $128,280
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 43 $43,664
Breo Ellipta Fluticasone/Vilanterol Brand 46 $35,503
Spiriva Handihaler Tiotropium Bromide Brand 23 $23,224
Spiriva Respimat Tiotropium Bromide Brand 14 $10,956
Symbicort Budesonide/Formoterol Fumarate Brand 25 $9,202
Albuterol Sulfate Hfa Albuterol Sulfate Brand 194 $8,234
Montelukast Sodium Generic 371 $6,234
Azithromycin Generic 295 $5,854

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$124,736

Of which drugs: $676

Medicare patients

516

Average age 76

Services billed

3,227

282 women, 234 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 50%
COPD 50%
Diabetes 41%
Heart failure 38%
Chronic kidney disease 37%
Atrial fibrillation 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 1,600 $158

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $33
  • GENZYME CORPORATION $32
$65 — —
NUCALA
  • GlaxoSmithKline, LLC. $32
$32 — —
YUPELRI
  • Mylan Specialty L.P. $19
$19 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record